Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute
Authors: Blase N. Polite, Lucile L. Adams‐Campbell, Otis W. Brawley, Nina Bickell, John M. Carethers, Christopher R. Flowers, Margaret Foti, Scarlett Lin Gomez, Jennifer J. Griggs, Christopher S. Lathan, Christopher I. Li, J. Leonard Lichtenfeld, Worta McCaskill‐Stevens, Electra D. Paskett
Journal: CA A Cancer Journal for Clinicians (2017)

The academic field of cancer health disparities was stimulated by the US civil rights movement. Concerns about civil rights led to concerns about equality in health care. The first publications to make the observation that black Americans have higher rates of death as a result of certain cancers compared with white Americans were published by the early 1970s.1, 2 The discipline concerned with these differences was first called "minority health research" and later "special populations health" or "special populations research." The National Cancer Institute (NCI) defines cancer health disparities as adverse differences in cancer incidence, cancer prevalence, cancer mortality, cancer survivorship, and burden of cancer or related health conditions that exist among specific population groups in the United States.3 However, with greater and renewed acknowledgment of health disparities as rooted within the context of historical and contextual inequities in the United States, many health disparities are considered health inequities.4 The National Cancer Act of 1971 created the Surveillance, Epidemiology, and End Results (SEER) program within the NCI. This program began collecting incidence, mortality, and survival data by race in the early 1970s from a number of population-based registries around the United States. The SEER program improved documentation of differences in outcomes and analyzed them through its black-white studies.5 These studies especially demonstrated differences in treatment patterns, with a higher proportion of blacks receiving inappropriate cancer care compared with whites. The discipline grew from a focus on black-white differences to encompass differences in outcomes for a number of racial and ethnic groups, as well as for cohorts defined by age, sex, socioeconomic status (SES), and other social determinants of health. There is now even greater appreciation for disparities among communities, whether rural versus urban or even by state or region. The definition of health outcomes also broadened beyond death rates. The field of health disparities was once simply a description of population differences and a call for cultural competence among health care providers. Today, the field is transdisciplinary, integrating basic science, clinical science, policy, epidemiology, and the social sciences. It involves people trained in diverse nonmedical fields, such as education, economics, sociology, religion, geography, and anthropology. The field is also dynamic. It changes as better and more granular statistics, greater understanding of causes of health disparities, and new challenges to mitigate these underlying causes have emerged. As an example, in the 1970s, the breast cancer death rate for black and white American women was the same. Today, the death rate is substantially higher for blacks compared with whites.6 Policy changes have also created opportunities and challenges. The Affordable Care Act has allowed for Medicaid expansion in each state. Expansion has been adopted by 32 states and the District of Columbia. This will create a new challenge, because poor residents of some states have expanded access to care and residents of other states do not. It is essential that any future policy changes should be carefully designed to increase, rather than decrease, equitable access to care throughout the cancer continuum. Population categorizations also are being redefined. The Asian category includes Korean Americans and Pakistani Americans. The Pacific Islander category, often merged with the Asian category, includes native Hawaiians and Samoans. These populations are incredibly heterogeneous and have dramatically different cancer statistics. In 2015, representatives from 4 leading cancer organizations-the American Association for Cancer Research, the American Cancer Society, the American Society for Clinical Oncology, and the NCI-began to meet to discuss the state of health disparities in the United States. These discussions involved the state of cancer health disparities research and what could be done to move it forward. The discussions were purposely not meant as a comprehensive review of cancer health disparities research. Rather, the meeting and the resulting document aimed to identify issues in health disparities research and make specific recommendations to improve the way disparities research is conducted and disseminated. This statement presents a unified strategy among 4 of the leading cancer organizations in the United States to promote cooperation among investigators in all areas of the cancer health disparities research community, to ensure that cancer research benefits all populations and patients regardless of race, ethnicity, age, gender identity, sexual orientation, SES, or the communities in which they live. Disparities in outcomes across the cancer continuum have been identified in numerous medically underserved populations, including racial and ethnic minorities and patients of lower SES. In addition to individual social status, social contextual and community factors, such as neighborhood safety, social cohesion, availability of healthy foods, and residential segregation, play an important role in the health of both individuals and populations. All of these factors can intersect to generate larger disparities.7, 8 To understand and fully address cancer health disparities, complete, consistent, and accurate collection of patient, community, and structural factors that put people at risk for disparate outcomes is essential. Unfortunately, cancer health disparities research has often been fraught with missing, inaccurate, or overly simplified patient-level data, and most research has failed to consider the community-level factors described above.9-11 For the most part, the manner in which data are collected and integrated in disparities research is suboptimal. The literature is characterized by variable methodology for collection of the factors that put patients and communities at risk for disparate care and outcomes. For example, although race and ethnicity are distinct constructs, they are often conflated such that a person is identified as Hispanic without identification of his or her race. Many studies that investigate cancer care or outcomes according to socioeconomic position have only area-level data on socioeconomic position, whereas others use only composite measures. While valuable in many cases in identifying disparities, such measures fall short in providing the richness of data needed to understand an individual's socioeconomic position. Health literacy and numeracy are rarely assessed in practice and are not available in administrative and research databases. Finally, methods for uniform data collection of information on sexual orientation and gender identity are in their infancy, despite calls for such data collection from the Institute of Medicine, among others.12 Disparities in cancer incidence are pronounced and longstanding. Drivers of these disparities are multifactorial and multilevel, and they include sociodemographic factors, access to health care, risk factor profiles and lifestyle/health habits, cultural perceptions, biologic differences, and genetic predisposition. Disparities in cancers for which single etiologic factors account for a substantial proportion of disease (eg, human papillomavirus and cervical cancer, or Helicobacter pylori and stomach cancer) can be reasonably understood and explained, but disparities for many of the common etiologically heterogeneous cancers, such as breast, prostate, and colorectal cancers, remain much less well understood. Multilevel approaches are needed to advance knowledge relevant to addressing disparities in cancer incidence rates. One approach is to design and implement observational studies focused on a population in which disparities exist to advance knowledge about etiology and to inform novel prevention strategies. A successful example of such an effort is the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium, a multicenter consortium that has combined data and biospecimens from 7500 African American patients with breast cancer and 17,000 healthy controls, representing the largest study of breast cancer in African American women in the United States.14 It has yielded a number of insights on multilevel risk factors specific to the major molecular subtypes of breast cancer among African American women.15-17 There is also a need for studies focused on identifying the genetic contributors to cancer health disparities. Recent work has focused on the prioritization of candidate variants relevant to prostate cancer risk within the context of genetic ancestry (based on ancestry informative markers) across those with European, African, Japanese, or Latino ancestry.18 Furthermore, the African Ancestry Prostate Cancer Genome-Wide Association Studies (GWAS) Consortium has reported on susceptibility loci for aggressive prostate cancer specific to men of African ancestry.19 Although some cancer risk factors are well established, the biologic mechanisms through which their impact on cancer risk varies across different populations remain incompletely understood. For example, variations in diet are hypothesized to be the primary driver of the dramatic variations in colorectal cancer incidence rates observed across populations. Recent research has evaluated the impact that different diets have on microbiota composition and function, which in turn affects the production of metabolites that either promote mucosal health or are pro-inflammatory/neoplastic in the gut. A study that compared Americans with African ancestry (who have a relatively high incidence of colorectal cancer) with rural South Africans (who have a comparatively very low colorectal cancer incidence rate) demonstrated that a typical US diet with high meat and fat intake increases mucosal proliferation rates (a marker of cancer risk) when fed to both populations, whereas typical high-fiber South African diets were associated with low proliferation rates when fed to both groups. This demonstrates that diet can have a profound and fairly immediate impact on the gut microbiome that can either promote or suppress tumors.20 Cancer outcome disparities are well documented for racial and ethnic minorities, and presentation at more advanced stages of cancer explains much of this difference. However, even when controlling for the stage of cancer at diagnosis, the survival disparities persist. What is most concerning is that rather than improving over time, for cancers such as colon cancer, the stage-specific disparities are actually worsening.21 The reason for this growing disparity is not completely clear but involves socioeconomic issues such as education status and the level of insurance and access to medical care. Even in studies that normalize socioeconomic issues (with the limitations cited in the "Defining Measures" section), disparities that disproportionally affect US minority populations can still be demonstrated for several cancers and may highlight the not so well understood interplay between genetic predisposition and environmental exposure, such as lifestyle and diet, that modifies cancer risk.22, 23 Ultimately, growing postdiagnosis survival disparities are caused by the interplay of system, social, biologic, and environmental factors. Documenting and addressing each of these and their interactions are key to eliminating these disparities. The role of system-level and social determinants in explaining cancer health disparities is best demonstrated by recognizing that disparities vary widely across the United States; some states show almost no disparities, whereas others show striking ones.24 We also know that disparities in the treatment of cancer differ and that when treatment differences are accounted for, either through the use of standardized therapies on a clinical trial or through multivariable modeling, cancer-specific survival disparities often disappear. We also have clear examples of successful system-level reform.21, 25, 26 We know, therefore, this is a solvable problem. The key step toward improving care and reducing cancer health disparities requires accurate measurement of meaningful variables, fed back in real time to key stakeholders in the system, followed by meaningful action and continued monitoring to ensure that the action was successful. Determining meaningful measurement across the cancer spectrum may vary by sociocultural factors and requires patient and stakeholder input. These system-based practices formed the core of a recent Institute of Medicine report, "Systems Practices for the Care of Socially At-Risk Populations."27 Systems can be thought of at a macro level, such as state, county, or city governments, all the way down to the individual practice or physician level. Implementation science can inform the best approaches to ensure delivery of high-quality cancer care. Cancers can start as a result of chronic inflammation, and inflammation can modify the behavior of cancer. Biomarkers, such as elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) that can be detected from inflammation-laden cancers, are associated with worse patient outcome and increased metastasis and appear to be more common among African Americans. Microsatellite-unstable (MSI) cancers, which have an overall good prognosis, may be one-half as common among African Americans compared with whites.28 Both EMAST and MSI have implications for 1) chemotherapeutic response and 2) immunotherapeutic response. In terms of race, these aspects have not been studied. Furthermore, there is much evidence that the microbiome can influence 1) inflammation, 2) response to chemotherapy, and 3) cancer or precancerous lesion formation; also, the microbiome itself can be determined by diet and other factors. These aspects have not been examined with race in mind. In addition, driver genes may be different within the same type of cancer from patients with different genetic backgrounds, which have implications for correct, definitive therapeutic approaches.29 Most studies that use human specimens to study aspects of cancer and race or ethnicity come from limited individual collections with sparse clinical-epidemiologic information, with rare exception. The exceptions tend to be NCI-funded projects, such as the North Carolina Colon Cancer Study, in which peer review and thoughtful input about how the collection was made with controls, surveys, and linked information to make the collection more meaningful, comprehensive in information, potentially useful for other future studies, and possessed of longevity. However, these types of collections or biorepositories, which include tumor and nontumor specimens, have not been created from diverse samples representative of the US Census population. Current models of health care delivery are highly focused on the use of technology and innovation to improve patient outcomes across disease processes, as demonstrated by the focus on precision medicine in cancer treatment.32-36 Although oncology attempts to embrace this approach, the impact of innovative treatments has been hampered by poor translation of innovation into health care systems and patients from diverse community settings.37, 38 As precision medicine in cancer is accelerated as part of the Beau Biden Cancer Moonshot and other initiatives, the importance of community engagement to ensure that all patients benefit from these advances cannot be overlooked. Cancer health disparities must be taken into consideration in the design, execution, and evaluation of all such programs. Community-engaged research (CER) has been documented as an effective, beneficial method for engaging communities and formulating research that has relevance and impact for both researchers and affected communities.39-42 Involving relevant community stakeholders in research at the planning stages allows for a deeper understanding of community needs, allows researchers to have an iterative method for evaluating research questions in an active realistic milieu, and simultaneously creates a valuable vehicle for active dissemination of the research findings into the communities they are intended to serve. CER offers the potential to improve processes and outcomes in several areas, including care delivery, continuity of care, managing comorbidities, and supportive care.42 Unfortunately, there is a dearth of support for oncology health professionals who choose to work in CER, given its necessity for infrastructure and relationship building, the complex personal interactions with communities and community organizations, and the need to establish long-term benefits to the community after the research project is completed. Importantly, CER requires not only a broad range of expertise across multiple disciplines, but also investigators skilled in a team science approach.43 The benefit of this type of team science has been touted across disciplines; however, its implementation has been limited.44 A lack of workforce diversity has been identified as a barrier to improving access to care for underserved minority groups as well as to advancing research on health disparities.45, 46 Organizations, including the American Society of Clinical Oncology and the American Society of Hematology, have sought to increase workforce diversity in oncology through awards and mentoring programs that expose underrepresented minorities to careers in oncology at the medical student, resident, and fellowship levels. In addition, the NCI Center to Reduce Cancer Health Disparities and the American Association for Cancer Research administer several programs aimed at training the next generation of competitive researchers in cancer and cancer health disparities research. Increased efforts of these types are needed to develop an oncology workforce that reflects the diversity of the patients it serves. Finally, CER does not often align with most traditional grant timelines and will require investment on behalf of the research institutions in both personnel and resources. Without such an investment, it will remain difficult to create a true synergy between CER and the rapid discoveries that occur in cancer research. Clinical trials are the most important and reliable means available to provide scientific evidence for effective care and management of patients with cancer and individuals at risk for cancer.47 Complex trials that incorporate advanced technologies necessitate new approaches from clinical care teams and diverse oncology practices. Because the putative goal of clinical trials is to provide evidence that is both valid and generalizable, future trials must include research questions that consider the multifactorial and multilevel components that characterize populations with the greatest cancer burden. This section proposes strategies to advance disparities research within the current cancer clinical trials system and/or within a new network of disparities-focused programs. Stringent criteria for participation in cancer clinical trials and common procedures for providing trial information have been barriers to enrollment for racial/ethnic minorities; rural residents; older patients (≥ 65 years); and patients with lower SES, limited English proficiency, low health literacy, and comorbidities. The high and increasing prevalence of chronic diseases and of risk factors for chronic diseases, such as obesity and early-onset diabetes, must inform eligibility criteria to represent these populations fully in cancer protocols. As an example, African Americans bear a disproportionate burden of the comorbidities that typically exclude participants from studies, and it is difficult to determine which comorbidities could be reasonably eliminated as exclusion criteria or could be sufficiently monitored or managed within the study framework.48 In addition to those front-end enrollment barriers, experience from cancer prevention and treatment trials also has shown that underrepresented populations often are enrolled later in the recruitment process, and subsequent power calculations frequently do not support subpopulation analyses. Recruitment and retention rates are key variables that influence the outcome of clinical cancer studies, particularly those trials in which minorities have disproportionately higher disease burdens, such as breast, prostate, colorectal, and lung cancers.49 In prevention, screening, and treatment trials, suboptimal recruitment and retention rates exist. Similarly, lower rates exist for those patients who transition from pediatric to adolescent and young adult cancers. Many issues, such as prevailing sociodemographics, trust issues, comorbidity burdens, and competing priorities, contribute to the situation.50 However, community engagement is vital to address the fundamental recruitment and retention challenges that cloud the clinical trials setting. CER has been demonstrated to promote trust, colearning, capacity building, and the sharing and dissemination of information needed for short- and long-term success.51 As an example, the Community-Based Retention Intervention Study evaluated the effectiveness of using community health advisors to promote retention and adherence in low-income and rural populations and found that community health advisors can be trained to serve as research partners and can be effective for improvement of retention and adherence.52 Finally, existing federally funded cancer clinical trial networks and pharmaceutical partners require an ever-complex array of biospecimens, often to be collected at multiple time points. More thought should be given to how best to augment the capacity of biospecimen teams and the study infrastructures (eg, surgical and pathology departments) needed to support collection and preparation of adequate specimens from low-resource institutions and centers that seek to recruit underrepresented populations. The field of cancer health disparities has evolved into a complex science and an established multidisciplinary field of cancer research. Unfortunately, the rigor required to conduct this research has not been uniformly applied, and the infrastructure needed to take it to the next level, where lasting solutions can be found, is limited. The purpose of this article, which has been jointly written by experts from these 4 esteemed organizations, is to guide the development of advances in this area. Our hope is that this statement will be used by both public and private organizations to inform specific investments made to improve cancer health disparities research, thereby ultimately eliminating identified disparities in cancer incidence, quality of care, and outcomes. We have clearly entered a new phase in cancer health disparities research—one that has the potential to benefit significantly from collaborations across disciplines and sectors. Given the looming crisis in cancer incidence and mortality disparities that affects minorities and the medically underserved, it is our collective hope that in this period of cancer research when significant breakthroughs are being discovered, there will be opportunities to apply this new knowledge to all populations, and thus eliminate cancer health disparities for current and future generations. Blase N. Polite has acted in a consulting or advisory role for AstraZeneca and Pfizer and as a paid member of the Speakers' Bureau for Bayer/Onyx, has received research funding from Merck, and has received other fees from the Gerson Lehrman Group for work performed outside of the current study. Christopher R. Flowers has acted as a paid consultant or in an advisory role for OptumRx, Seattle Genetics, Bayer, and Gilead Sciences; has received research funding via his institution from Acerta Pharma, Infinity Pharmaceuticals, Onyx, Janssen Oncology, Gilead Sciences, Celgene, TG Therapeutics, Genentech, Roche, Pharmacyclics, AbbVie, and Immune Design; and has received travel and accommodations expenses from Gilead Sciences, Celgene, Genentech, and Roche for work performed outside of the current study. Christopher S. Lathan has received honoraria from PER; has acted in a consulting or advisory role for the Gerson Lehrman Group, Lilly, and Bristol-Myers Squibb; and has received research funding from CVS Health for work performed outside of the current study. J. Leonard Lichtenfeld reports stock or other ownership in General Electric, IBM, and Johnson & Johnson; has received honoraria from Aetna; and has received travel and accommodations expenses from Aetna for work performed outside of the current study. Electra D. Paskett reports stock or other ownership in Pfizer, Pfizer (I), Meridian Bioscience, and Meridian Bioscience (I) and has received research funding to her institution from Merck Sharp & Dohme. All remaining authors report no conflicts of interest. We thank the leadership of AACR, ACS, ASCO, and the NCI for their stewardship of this process. Special thanks to Tawanna Brooks, Lyngine Calizo, Michael Francisco, Barry Kramer, Christine Rullo, and Dana Wollins.